PET for Dementia Trials

Additionally, in a National Coverage Determination for PET (FDG) for Dementia and Neurodegenerative Diseases (220.6.13) the Centers for Medicare & Medicaid Services (CMS) indicated that an FDG-PET scan is considered reasonable and necessary in patients with mild cognitive impairment or early dementia only in the context of an approved clinical trial that contains patient safeguards and protections to ensure proper administration, use and evaluation of the FDG-PET scan.

Showing 1-6 of 6 entries
Facility name Provider Number Date approved State
Cedars-Sinai Medical Center 95 1644600 2009-10-09 CALIFORNIA
Center for Alzheimer's Care, Imaging and Research (University of Utah) 460009 2009-02-17 UTAH
Medical University of South Carolina 1073605879 2009-02-17 SOUTH CAROLINA
Santa Monica-UCLA Medical Center W11817A 2007-01-12 CALIFORNIA
UCLA Medical Center HW13029 2006-06-07 CALIFORNIA
University of Buffalo 14414A 2007-03-12 NEW YORK
Page Last Modified:
12/01/2021 07:02 PM